Close Menu


Norcross, Ga.-based RayBiotech has launched a partnering program to provide its proteomic analysis services through diagnostic core facilities at academic and government research institutes in the US and Canada.

NEW YORK (GenomeWeb News) – RayBiotech today announced a deal with Innopsys to co-market each other's technologies.

Using gene expression data combined with bioinformatic analyses, scientists at the University of Georgia and China's Jilin University are developing a urine-based protein biomarker test for gastric cancer that they hope to offer as a direct-to-consumer diagnostic.

New Product Watch: Apr 5, 2011


Affymetrix's OncoScan FFPE Express 2.0, PerkinElmer's OncoChip, HTG Molecular Diagnostics' qFix Arrays, RayBiotech's Biostatistics and Bioinformatics Program

The company will use the NIH grant to develop protein biomarkers for use in developing diagnostics for endometriosis.

The companies are developing kits that combine Gentel's APiX technology and RayBiotech's collection of more than 55 antibody and protein arrays on a glass slide format.

Gentel plans to add 50 new kits to its product portfolio by the end of the year, as it transforms itself from being a services-oriented business to one that derives the bulk of its sales from products.

New Product Watch: Dec 15, 2009


Oxford Gene Technology, RayBiotech

BioArray Briefs: Apr 28, 2009


23andMe, Palomar Pomerado Health, Sequenom, Satoris, RayBiotech, University of Griefswald, InforSense, Institute of Molecular and Medical Genetics, CapitalBio, BioTools

Snippets: Apr 22, 2009


Johns Hopkins University's Genetics and Public Policy Center, National Cancer Institute, Santoris, RayBiotech


A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.